These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 29230217)

  • 1. Type I Interferons in the Pathogenesis of Tuberculosis: Molecular Drivers and Immunological Consequences.
    Donovan ML; Schultz TE; Duke TJ; Blumenthal A
    Front Immunol; 2017; 8():1633. PubMed ID: 29230217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Evolution of IGRA researches].
    Ariga H; Harada N
    Kekkaku; 2008 Sep; 83(9):641-52. PubMed ID: 18979999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type I, II, and III Interferons: Regulating Immunity to Mycobacterium tuberculosis Infection.
    Travar M; Petkovic M; Verhaz A
    Arch Immunol Ther Exp (Warsz); 2016 Feb; 64(1):19-31. PubMed ID: 26362801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamic changes in pro- and anti-inflammatory cytokine profiles and gamma interferon receptor signaling integrity correlate with tuberculosis disease activity and response to curative treatment.
    Sahiratmadja E; Alisjahbana B; de Boer T; Adnan I; Maya A; Danusantoso H; Nelwan RH; Marzuki S; van der Meer JW; van Crevel R; van de Vosse E; Ottenhoff TH
    Infect Immun; 2007 Feb; 75(2):820-9. PubMed ID: 17145950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR-23a-5p modulates mycobacterial survival and autophagy during mycobacterium tuberculosis infection through TLR2/MyD88/NF-κB pathway by targeting TLR2.
    Gu X; Gao Y; Mu DG; Fu EQ
    Exp Cell Res; 2017 May; 354(2):71-77. PubMed ID: 28327409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inborn errors of interferon (IFN)-mediated immunity in humans: insights into the respective roles of IFN-alpha/beta, IFN-gamma, and IFN-lambda in host defense.
    Zhang SY; Boisson-Dupuis S; Chapgier A; Yang K; Bustamante J; Puel A; Picard C; Abel L; Jouanguy E; Casanova JL
    Immunol Rev; 2008 Dec; 226():29-40. PubMed ID: 19161414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of Interferons in
    Shanmuganathan G; Orujyan D; Narinyan W; Poladian N; Dhama S; Parthasarathy A; Ha A; Tran D; Velpuri P; Nguyen KH; Venketaraman V
    Clin Pract; 2022 Sep; 12(5):788-796. PubMed ID: 36286068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Drug-Sensitive and -Resistant Strains of Mycobacterium tuberculosis by Inhibition of Src Family Kinases Lowers Disease Burden and Pathology.
    Chandra P; Rajmani RS; Verma G; Bhavesh NS; Kumar D
    mSphere; 2016; 1(2):. PubMed ID: 27303736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TLR-4/miRNA-32-5p/FSTL1 signaling regulates mycobacterial survival and inflammatory responses in Mycobacterium tuberculosis-infected macrophages.
    Zhang ZM; Zhang AR; Xu M; Lou J; Qiu WQ
    Exp Cell Res; 2017 Mar; 352(2):313-321. PubMed ID: 28215633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjunctive biomarkers for improving diagnosis of tuberculosis and monitoring therapeutic effects.
    Hur YG; Kang YA; Jang SH; Hong JY; Kim A; Lee SA; Kim Y; Cho SN
    J Infect; 2015 Apr; 70(4):346-55. PubMed ID: 25452040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mycobacterial interaction with innate receptors: TLRs, C-type lectins, and NLRs.
    Jo EK
    Curr Opin Infect Dis; 2008 Jun; 21(3):279-86. PubMed ID: 18448973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autophagy as an innate defense against mycobacteria.
    Jo EK
    Pathog Dis; 2013 Mar; 67(2):108-18. PubMed ID: 23620156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interactions between Type 1 Interferons and the Th17 Response in Tuberculosis: Lessons Learned from Autoimmune Diseases.
    Mourik BC; Lubberts E; de Steenwinkel JEM; Ottenhoff THM; Leenen PJM
    Front Immunol; 2017; 8():294. PubMed ID: 28424682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon gamma release assays: principles and practice.
    Lalvani A; Pareek M
    Enferm Infecc Microbiol Clin; 2010 Apr; 28(4):245-52. PubMed ID: 19783328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathogenicity of Type I Interferons in
    Mundra A; Yegiazaryan A; Karsian H; Alsaigh D; Bonavida V; Frame M; May N; Gargaloyan A; Abnousian A; Venketaraman V
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tuberculosis in compromised hosts].
    Kekkaku; 2003 Nov; 78(11):717-22. PubMed ID: 14672050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune Responses to Bacillus Calmette-Guérin Vaccination: Why Do They Fail to Protect against
    Moliva JI; Turner J; Torrelles JB
    Front Immunol; 2017; 8():407. PubMed ID: 28424703
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.